

LOUISIANA DRUG UTILIZATION REVIEW BOARD AGENDA

April 23, 2026, 3:00 PM, Baton Rouge, LA

The items on this discussion list apply to FFS and MCO unless otherwise noted.

Call to Order		Peggy Dean	
Introductions		Peggy Dean	
Review of January 22, 2026 Minutes		Peggy Dean	
POS and Clinical Criteria Proposals (Vote Required)	1.	VYSCOXA™ (celecoxib) Oral Suspension: New Formulation – Add quantity limit, age limit, & concurrent use; modify non-preferred criteria	Beverly Walker
	2.	TONMYA™ (cyclobenzaprine) 2.8 mg Sublingual Tablet: New Dosage Formulation – Add quantity limit	Beverly Walker
	3.	LYNKUET® (elinzanetant): New Drug – Add quantity limit & clinical criteria	Beverly Walker
	4.	ORLYNVAH™ (sulopenem etzadroxil and probenecid): New Drug – Add quantity limit & clinical criteria	Beverly Walker
	5.	PAPZIMEOS™ (zopapogene imadenovec-drba): New Gene Therapy – Add clinical criteria	Beverly Walker
	6.	DESLORATIDINE 0.5 mg/mL Oral Solution: New Formulation – Add quantity limits	Melissa Dear
	7.	ITVISMA® (onasemnogene abeparvovec-brve): New Gene Therapy – Add clinical criteria	Melissa Dear
	8.	VOYXACT® (sibeprenlimab-szsi): New Drug – Add diagnosis code requirement & quantity limit	Melissa Dear
	9.	EXDENSUR (depemokimab-ulaa): New Drug - Add diagnosis code-specific quantity limit & clinical criteria	Melissa Dear
	10.	FORZINITY™ (elamipretide): New Drug – Add clinical criteria	Melissa Dear
	11.	REDEMPLLO® (plozasiran): New Drug – Add clinical criteria	Beverly Walker
	12.	AQVESME™ (mitapivat) tablets: New Drug – Add quantity limit & clinical criteria	Beverly Walker
	13.	YARTEMLEA® (narsoplimab-wuug): New Drug – Add clinical criteria	Beverly Walker
	14.	BLUJEPA (gepotidacin): New Drug: Add quantity limit & clinical criteria with a bypass diagnosis	Beverly Walker
	15.	ZEPBOUND KWIKPEN® (tirzepatide): New Dosage Formulation: Add quantity limit	Beverly Walker
	16.	ZYCUBO® (copper histidinate): New Drug – Add clinical criteria	Melissa Dear
	17.	Inhaled Tobramycin: Expand diagnosis code requirements	Melissa Dear
	18.	Misoprostol: Modify diagnosis code requirements	Melissa Dear
	19.	Skeletal Muscle Relaxants, Multivitamins, Pediatric Multivitamins, Sedative/Hypnotics, & NSAIDs: Modification of authorization criteria	Melissa Dear
	20.	MYQORZO™ (aficamten): New Drug: Add quantity limit & clinical criteria	Melissa Dear
	21.	STARJEMZA™ (ustekinumab-hmny): New Biosimilar – Add clinical criteria	Beverly Walker
Clinical Updates (No Vote Required)	22.	UPLIZNA® (inebilizumab-cdon): New Indication – Modify existing clinical criteria to include new indication	Beverly Walker
	23.	CAPLYTA® (lumateperone): New Indication – Modify diagnosis code requirements to include new indication <i>(Implemented 2/1/2026)</i>	Beverly Walker

	24.	VRAYLAR® (cariprazine): Expanded Indications – Modify aged-based maximum daily doses for expanded indications	Beverly Walker
	25.	QELBREE™ (viloxazine): Modify quantity limits	Beverly Walker
	26.	MOUNJARO® (tirzepatide): Expanded Indication – Modify existing clinical criteria to include expanded age <i>(Implemented: 2/1/2026)</i>	Melissa Dear
	27.	ORLADEYO® (berotralstat): Expanded Indication/New Formulation – Modify existing clinical criteria to include expanded age	Melissa Dear
	28.	EXXUA™ (gepirone) ER Titration Pack: New Formulation – Add quantity limit	Melissa Dear
	29.	LEQVIO® (inclisiran): Expanded Indication – Modify existing clinical criteria to include expanded age	Melissa Dear
	30.	JUXTAPID® (lomitapide): Expanded Indication - Modify existing clinical criteria to include expanded age	Melissa Dear
	31.	DUPIXENT® (dupilumab): New Indication – Modify existing diagnosis-specific quantity limit and clinical criteria to include new indication	Melissa Dear
RetroDUR	30.	LADUR Report	Megan Guidry